Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2

Abstract
Excessive type I interferon (IFNα/β) activity is implicated in a spectrum of human disease, yet its direct role remains to be conclusively proven. We investigated two siblings with severe early-onset autoinflammatory disease and an elevated IFN signature. Whole-exome sequencing revealed a shared homozygous missense Arg148Trp variant in STAT2, a transcription factor that functions exclusively downstream of innate IFNs. Cells bearing STAT2R148W in homozygosity (but not heterozygosity) were hypersensitive to IFNα/β, which manifest as prolonged Janus kinase–signal transducers and activators of transcription (STAT) signaling and transcriptional activation. We show that this gain of IFN activity results from the failure of mutant STAT2R148W to interact with ubiquitin-specific protease 18, a key STAT2-dependent negative regulator of IFNα/β signaling. These observations reveal an essential in vivo function of STAT2 in the regulation of human IFNα/β signaling, providing concrete evidence of the serious pathological consequences of unrestrained IFNα/β activity and supporting efforts to target this pathway therapeutically in IFN-associated disease.
Funding Information
  • Wellcome Trust (211153/Z/18/Z)
  • Wellcome Trust (207556/Z/17/Z)
  • Wellcome Trust (101788/Z/13/Z)
  • Medical Research Council (MR/N013840/1)
  • Medical Research Council
  • National Institute for Health Research (TRF-2016-09-002)
  • Sir Jules Thorn Charitable Trust (12/JTA)
  • European Research Council (GA 309449)
  • Agence Nationale de la Recherche (ANR-10-IAHU-01)
  • Agence Nationale de la Recherche (CE17001002)
  • Kidney Research UK
  • Agence Nationale de la Recherche (CE17001002)
  • British Infection Association (Research Fellowship)
  • Deutsche Forschungsgemeinschaft (GO 2955/1-1)